title: Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when?
abstract: OBJECTIVE
  To ascertain when the serum determination of the free prostate-specific antigen (PSA)/total PSA (fPSA/tPSA) ratio is clinically useful, and whether the identification of PSA or prostate-specific membrane antigen (PSM) mRNA in circulating cells has diagnostic advantages over the determination of their protein product.
  
  
  METHODS
  fPSA, tPSA, and the fPSA/tPSA ratio were determined in the sera of 50 men with benign nonprostatic urologic diseases (EPD), 112 patients with prostate cancer (PCa), and 218 with benign prostatic hyperplasia (BPH). mRNA was extracted from the circulating mononuclear cells of 13 EPD samples, 25 PCa samples, and 38 BPH samples. PSA and PSM mRNA signals were identified in these samples by means of reverse transcriptase-polymerase chain reaction.
  
  
  RESULTS
  Overall, at a fixed specificity of 95%, the sensitivity of tPSA was 19% and that of the fPSA/tPSA ratio was 40% in distinguishing PCa from BPH. The fPSA/tPSA ratio allowed the discrimination of PCa from BPH with satisfactory sensitivity and specificity when considering patients less than 60 years of age (100% and 95%, respectively). PSA and PSM mRNA were positive in 1 and 7 of 13 EPD samples, 6 and 13 of 25 PCa samples, and 6 and 17 of 38 BPH samples. The Gleason score did not correlate with tPSA, the fPSA/tPSA ratio, PSA mRNA, or PSM mRNA.
  
  
  CONCLUSIONS
  The serum determination of the fPSA/tPSA ratio is an excellent index of PCa for subjects younger than 60 years of age; the clinical utility of PSA mRNA identification in circulating cells needs to be validated by large follow-up studies, and the analysis of PSM mRNA seems to be of no clinical interest.
authors.affiliation: Department of Laboratory Medicine, University-Hospital of Padova, Padova, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Basso
authors.forename: P
authors.initials: P
authors.lastname: Fogar
authors.forename: M G
authors.initials: MG
authors.lastname: Piva
authors.forename: F
authors.initials: F
authors.lastname: Navaglia
authors.forename: S
authors.initials: S
authors.lastname: Mazza
authors.forename: T
authors.initials: T
authors.lastname: Prayer-Galetti
authors.forename: E
authors.initials: E
authors.lastname: Castellucci
authors.forename: F
authors.initials: F
authors.lastname: Pagano
authors.forename: M
authors.initials: M
authors.lastname: Plebani
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000235:genetics; D011470:Prostatic Hyperplasia / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis*; D012333:RNA, Messenger / Q000097:blood; D012680:Sensitivity and Specificity
chemical_list: D012333:RNA, Messenger; D017430:Prostate-Specific Antigen